Avivagen Passes National Animal Supplement Council Certification Audit
from Thenewswire.ca - RSS (all) by news@thenewswire.ca (TheNewswire.ca)
OTTAWA, ONTARIO, February 23, 2012 - Avivagen Animal Health, a wholly-owned subsidiary of Chemaphor Inc. (the "Company"; TSX Venture Exchange: CFR), is pleased to announce that the National Animal Supplement Council (NASC) has awarded Avivagen Animal Health, Inc. (Avivagen) a compliance rating of "A" with a 2-year NASC Certification. As an NASC member, Avivagen Animal Health is now authorized to carry the NASC Quality Seal on Oximunol(TM) Chewables for dogs and on its other companion animal products currently in development, as well as to display the seal on its website. Avivagen's Oximunol(TM) Chewables are being sold in Canada and will be introduced to the US companion animal veterinary market later this year under the distribution agreement recently announced with Teva Animal Health, Inc.
"Receiving the NASC endorsement is a major company achievement for marketing our companion animal products in North America, and the US in particular," said David Hankinson, CEO of Chemaphor. "The audit was a rigorous and valuable process for Avivagen. Compliance with NASC's standards is all about providing a level of independent reassurance to customers that Avivagen manufactures its products to Good Manufacturing Practices standards and that it adheres to a complete set of written Standard Operating Procedures covering all aspects of the product, including manufacture, labeling, dissemination of product information in all forms, and the NASC Adverse Event Reporting System (NAERS). We are delighted with the excellent outcome of the evaluation of the processes we have in place to ensure production of the highest quality products."
About Avivagen
Avivagen Animal Health Inc., a wholly-owned subsidiary of Chemaphor, is a Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials. More information can be found at www.avivagen.com.
About Chemaphor
Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.
About NASC
The National Animal Supplement Council is a not-for-profit trade organization dedicated to protecting and enhancing the health of companion animals and horses throughout the United States through its ongoing effort to improve and standardize the animal health supplement industry. For more information please visit www.nasc.cc.
Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
David Hankinson Graham Burton, PhD
CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.
Phone: 902-825-9270 Phone: 613-990-0969
d.hankinson@chemaphor.com g.burton@chemaphor.com
Investor Relations: Media Group:
Advent Management Inc. McCormick Global Communications President & CEO Karen Sample
Sylvain Archambault 519-475-6378 1-877-906-2425 ksample@mccormickglobal.com s.archambault@go-advent.com www.mccormickglobal.com |
